HOME >> BIOLOGY >> NEWS
Joslin scientists confirm link between PKC enzyme and kidney disease in diabetes

BOSTON - Scientists at Joslin Diabetes Center have investigated PKC-beta - a critical enzyme implicated in the devastating complications of type 1 and type 2 diabetes - for more than two decades. Their latest research, to be presented June 11 at the American Diabetes Association's (ADA) 65th Scientific Sessions in San Diego, Calif., confirms the link between hyperglycemia (high blood glucose), overexpression of PKC-beta 2 and kidney disease.

The poster is one of 89 presentations Joslin scientists will deliver at the ADA Scientific Sessions, to be held Friday, June 10, through Tuesday, June 14 at the San Diego Convention Center. Some 13,000 scientists, physicians and health professionals from around the world will attend the conference, to be held at the San Diego Convention Center. (Abstract Number: 849-P)

"The significance of this study is that we found strong evidence linking chronic activation of a specific form of the PKC enzyme - beta 2 - to the abnormal kidney changes and oxidative stress seen in diabetes," said George L. King, M.D., the study's lead author, Joslin's Director of Research, Head of the Section on Vascular Cell Biology, and a Professor of Medicine at Harvard Medical School. Other investigators in the study included previous Joslin fellows Yutaka Yasuda, M.D., Ph.D., and Noriko Takahara, M.D., as well as Timothy S. Kern, Ph.D., of Case Western Reserve Medical School, Cleveland, Ohio.

Protein kinase C (PKC) is an enzyme essential to the normal functions of the cell and the body. The PKC family of enzymes, which helps regulate many blood vessel functions, comprises about a dozen different molecular forms, or isoforms, including PKC-alpha, PKC-beta 1, PKC-beta 2 and PKC-delta.

In this study, Dr. King and his colleagues proposed that chronic activation or overexpression of the PKC-beta 2 isoform plays an important role in the progression of diabetic kidney disease. To test this hypothesis, researchers used genetic enginee
'"/>


11-Jun-2005


Page: 1 2 3

Related biology news :

1. Joslin study indicates insulin receptors play a critical role in promoting islet growth
2. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects
3. Joslin study reveals how a specific fat type can protect against weight gain and diabetes
4. Joslin discovers protein that causes blood vessel leakage and swelling with diabetic retinopathy
5. Joslin-led study uncovers role of appetite hormone MCH in insulin production
6. Joslin Diabetes Center study examines insulin pump therapy in adolescents
7. Joslin Diabetes Center in Boston establishes first affiliate in Canada
8. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
9. Joslin awards Victory Medal to New York man living 75 years with type 1 diabetes
10. Joslins new book demystifies nutrition and meal planning for people with diabetes
11. Joslin study refutes recent report that bone marrow can replenish female oocytes

Post Your Comments:
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: